GlobeNewswire

MSAB: Continued investment for growth

Share

January - June

  • Net sales increased 1.6 percent to SEK 130.4 (128.3) million (-4 percent in local currencies).
  • EBIT amounted to SEK -17.1 (3.8) million.
  • The EBIT margin was -13.1 (3.0) percent.
  • Profit after tax amounted to SEK -15.3 (5.7) million.
  • Earnings per share amounted to SEK -0.83 (0.31).
  • Cash flow from operating activities amounted to SEK -6.2 (-11.1) million.
  • Cash and cash equivalents and short-term investments amounted to SEK 52.5 (80.4) million at the end of the period.

Second quarter

  • Net sales increased 1.7 percent to SEK 64.1 (63.0) million (-4 percent in local currencies).
  • EBIT amounted to SEK -11.4 (0.1) million.
  • The EBIT margin was -17.8 (0.2) percent.
  • Profit after tax amounted to SEK -10.8 (1.3) million.
  • Earnings per share amounted to SEK -0.58 (0.07).
  • Cash flow from operating activities amounted to SEK 0.7 (-11.4) million.

Comments from the CEO


Sales amounted to SEK 130.4 (128.3) million for the first six months of the year. EBIT came in at SEK -17.1 (3.8) million, the decline in profit resulting from a decrease in new sales, combined with continued investments within product development and marketing with the aim of generating future growth. For the second quarter, sales reached SEK 64.1 (63.0) million.

Growth for the first half of 2019 is not to my satisfaction. The market for mobile forensics carries significantly greater potential than what is visible in our numbers. Income from license renewals continues to grow, which demonstrates that our existing customers are satisfied with the systems they have invested in. My dissatisfaction lies primarily with new sales.

Our greatest growth potential lies in the decentralised solutions which we call Frontline. Decentralised solutions mean that police, who currently seize suspects’ mobile phones and send them elsewhere for analysis, can instead easily extract data themselves from the phones. In this way, they can quickly take advantage of important information, thereby solving and preventing crime more effectively. One of the reasons that new sales of these systems is lagging is that they entail a whole new way of working for the police. Changing ways of working takes time in large organisations. Nevertheless, the vast majority of customers realise the enormous benefits of decentralisation, but it takes time to decide where the responsibility for these solutions should lie.

I can also report that those customers that have invested in and have experience with our Frontline solutions are very satisfied. In my assessment, MSAB is the company that has delivered the greatest number of decentralised solutions world-wide. We have however seen a trend towards more aggressive price-setting from competitors to win these deals.

We have customers who have been using our systems for many years, and some customers extract data from up to 700 phones per day with XRY. This means that XRY handles extremely large amounts of information every day, and this makes an enormous difference in creating a safer and more secure society.

We continuously develop our product portfolio. Most recently, we released a new version of XRY, that extracts more data in a shorter time and with a significantly improved user experience. Besides offering a strong concept for extracting information from mobile phones, we even have tools for efficient analysis of data from mobile phones through our XAMN products. Thanks to our unique way of sorting data immediately as the mobile phone is being read, in combination with smart AI functions, our products can also analyse vast quantities of data in a short time. With high precision, we can present data relevant to the criminal investigation that the investigator is working on in the moment.

During the third quarter, the company will also carry out some process- and organizational changes in order to strengthen our product offering and intensify our marketing activities. The purpose of these changes is to increase growth and profitability of the company.

MSAB is a company on a market with all the prerequisites for growth and healthy profitability. 

Stockholm, July 2019

Joel Bollö

Chief Executive Director

The information in this report is such that MSAB, Corporate ID number 556244-3050, is required to disclose in accordance with the EU’s Market Abuse Regulation. The information in this report was submitted for publication on 19 July, 2019 at 08:00 CEST through the offices of the contact person listed below.

Questions should be addressed to:
Chief Executive Officer Joel Bollö
Tel. +46 8 739 0270
Email: joel.bollo@msab

MSAB in brief
MSAB is a world leader in mobile forensics technology with the aim of extracting and analysing data from confiscated mobile devices, mainly from mobile phones. The Company has its own sales offices and sales representatives in Europe, North America, South America, China, Australia, Singapore, Japan and Russia, and together with a number of distributors, covers most of the world. The proprietary products have become a de facto standard in the field and are used for securing evidence in more than 100 countries. These products are complemented by a wide range of training courses with the possibility of becoming certified in a forensically sound methodology. Customers are primarily law enforcement agencies, such as police, military and customs. MSAB is listed on NASDAQ Stockholm under the ticker symbol: MSAB B.

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Sista dag för handel med BTA B i Oboya6.12.2019 13:14:00 CETPressemelding

Oboya Horticulture Industries AB: s (” Oboya” eller” Bolaget”) företrädesemission har registrerats vid Bolagsverket. Sista dag för handel i Bolagets betalda tecknade aktier, OBOYA BTA B, är den 11 december 2019. Stoppdag hos Euroclear för växling från BTA till aktier är den 13 december 2019. De nya aktierna beräknas bokas ut på respektive aktieägares VP-konto/depå den 17 december 2019. Efter registrering av företrädesemissionen och den kvittningsemission som offentliggjordes den 25 november 2019 uppgår Oboyas aktiekapital till 1 256 175,08 SEK och antalet B-aktier till 34 485 918. Rådgivare Augment Partners AB är finansiell rådgivare och Hamilton Advokatbyrå KB är legal rådgivare till Oboya i samband med Företrädesemissionen. Aqurat Fondkommission AB agerar emissionsinstitut. För mer information, vänligen kontakta: Robert Wu, VD Oboya Horticulture Industries AB (publ) Tel: + 86 159 6983 5999 E-post: robert.wu@oboya.cc Hemsida: www.oboya.se Erik Penser Bank AB är Oboyas Certified Advise

Medtronic Announces Cash Dividend for Third Quarter of Fiscal Year 20206.12.2019 12:45:00 CETPress release

DUBLIN, Dec. 06, 2019 (GLOBE NEWSWIRE) -- The board of directors of Medtronic plc (NYSE:MDT) today approved the fiscal year 2020 third quarter cash dividend of $0.54 per ordinary share, representing an 8 percent increase over the prior year. This quarterly declaration is consistent with the dividend announcement made by the company in June 2019. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 42 consecutive years. The dividend is payable on January 17, 2020, to shareholders of record at the close of business on December 27, 2019. About Medtronic Medtronic plc ( www.medtronic.com ), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 count

Oasmias företrädesemission övertecknad6.12.2019 12:25:00 CETPressemelding

Det preliminära utfallet i företrädesemissionen i Oasmia Pharmaceutical AB (publ) (”Oasmia” eller “Bolaget”), vars teckningsperiod avslutades den 4 december 2019, visar att 198 329 980 aktier tecknats i företrädesemissionen med stöd av teckningsrätter, vilket motsvarar cirka 99,5 procent av företrädesemissionen. Därutöver har Bolaget mottagit anmälningar om att teckna 78 277 041 aktier utan stöd av teckningsrätter, vilket motsvarar cirka 39,3 procent av företrädesemissionen. Företrädesemissionen är därmed övertecknad. ”Jag är mycket nöjd med utfallet i företrädesemissionen samt är tacksam för det stöd vi fått från våra aktieägare. Jag är imponerad av Oasmias ledningsgrupps prestationer, då de under press visat marknaden deras förmåga att utveckla Oasmia till en kommersiell organisation med en spännande framtida agenda”, kommenterar styrelseordförande Jörgen Olsson. Det preliminära utfallet i Oasmias företrädesemission, vars teckningsperiod löpte från och med den 20 november 2019 till o

Oasmia’s rights issue has been oversubscribed6.12.2019 12:25:00 CETPress release

The preliminary result of the rights issue in Oasmia Pharmaceutical AB (publ) (”Oasmia” or the “Company”), in which the subscription period ended on 4 December 2019, amounts to 198,329,980 shares subscribed for in the rights issue with subscription rights, which corresponds to approximately 99.5 percent of the rights issue. In addition, the Company has received applications to subscribe for 78,277,041 shares without subscription rights, corresponding to approximately 39.3 percent of the rights issue. Thus, the rights issue has been oversubscribed. “I am very pleased with the outcome in the rights issue, and grateful for the support from our shareholders. I’m impressed by the Oasmia team’s performance to, under pressure, show the market their determination to transform Oasmia into a commercial entity with a thrilling agenda going forward”, comments Jörgen Olsson, Chairman of the Board. The preliminary result of the rights issue in Oasmia, in which the subscription period took place from

Result of Riksbank reversed auctions SEK bonds6.12.2019 10:07:00 CETPress release

Auction date 2019-12-06 Loan 3109 Coupon 1.00 % ISIN-code SE0005703550 Maturity 2025-06-01 Tendered volume, SEK mln 250 +/- 250 Volume offered, SEK mln 750 Volume bought, SEK mln 250 Number of bids 5 Number of accepted bids 2 Average yield -1.917 % Lowest accepted yield -1.929 % Highest yield -1.899 % % accepted at lowest yield 60.00 Auction date 2019-12-06 Loan 3113 Coupon 0.125 % ISIN-code SE0009548704 Maturity 2027-12-01 Tendered volume, SEK mln 250 +/- 250 Volume offered, SEK mln 450 Volume bought, SEK mln 250 Number of bids 4 Number of accepted bids 1 Average yield -1.855 % Lowest accepted yield -1.855 % Highest yield -1.855 % % accepted at lowest yield 100.00

ASM INTERNATIONAL TO HOST TECHNOLOGY SEMINAR6.12.2019 10:00:00 CETPress release

Almere, The Netherlands December 6, 2019 ASM International N.V. (Euronext Amsterdam: ASM) today announces that it will host a technical luncheon seminar in San Francisco, CA, US, on Wednesday, December 11, 2019, the third day of the IEDM Conference. At this technology seminar, ASM will highlight the challenges and potential solutions for metallization applications. The agenda is as follows: 11:30 am Reception, food and drinks 12:00 - 12:15 pm Welcome and introduction 12:15 - 1:00 pm Invited speaker: Dr. Raghuveer Makala (Western Digital) - "Metallization Challenges in 3D NAND Flash" Following the presentations, there is an opportunity for open discussion and networking until 1:15 pm. The ASM technology seminar will take place in the Golden Gate room (25th floor) at the Nikko Hotel (across from the Hilton San Francisco), San Francisco, CA 94102. The room will open at 11:30 am for invited attendees. Interested parties should contact Rosanne de Vries, +31 88 100 8569, Rosanne.de.Vries@asm